Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06650833/PF-06651600/tofacitinib combination study in methotrexate-inadequate responder rheumatoid arthritis
2019-002676-14Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing PF-06650833 + PF-06651600, PF-06650833 + Xeljanz and Xeljanz alone (3 arms). Primary endpoint: Change from baseline in DAS28-CRP at Week 12. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-002676-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002676-14.